Sperimentazioni cliniche attive

AMILOIDOSI AL

A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis.

A phase II open-label randomized study of dietary supplement with epigallocatechin gallate (EGCG) to improve cardiac dysfunction in patients with AL amyloidosis who do not require chemotherapy (EpiCardiAL).

An open-label, phase II study of pomalidomide and dexamethasone (PDex) for previously treated patients with AL amyloidosis.

An Open Label Phase II Trial of Free Light Chain Removal by Extended High Cut-Off Hemodialysis in Patients with Advanced Cardiac AL Amyloidosis and End-Stage Renal Disease (DiACAL).

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed/Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment.

AMILOIDOSI ATTR

Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis.

The effect of Diflunisal on familial amyloidosis (IND 68092): A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal. A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects.

A single center, twelve-month, open-label, prospective study followed by a six-month withdrawal period to evaluate the efficacy, tolerability, safety and pharmacokinetics (PK) of dosycycline in combination with tauroursodeosycholic acid (TUDCA) in adults with transthyretin amyloidosis (ATTR).

SINDROME AUTOINFIAMMATORIA TRAPS

An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).

AMILOIDOSI AA

International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Funcion Decline in Patients With AA Amyloidosis.